Next Article in Journal
Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
Next Article in Special Issue
The Potential Role of Osteopontin and Furin in Worsening Disease Outcomes in COVID-19 Patients with Pre-Existing Diabetes
Previous Article in Journal
The PTEN Conundrum: How to Target PTEN-Deficient Prostate Cancer
Previous Article in Special Issue
Disharmonic Inflammatory Signatures in COVID-19: Augmented Neutrophils’ but Impaired Monocytes’ and Dendritic Cells’ Responsiveness
Review

The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies

Turku Bioscience Centre, University of Turku and Åbo Akademi University, 20520 Turku, Finland
*
Author to whom correspondence should be addressed.
Cells 2020, 9(11), 2343; https://doi.org/10.3390/cells9112343
Received: 29 September 2020 / Revised: 20 October 2020 / Accepted: 21 October 2020 / Published: 22 October 2020
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of the Coronavirus disease (COVID-19) pandemic, has so far resulted in more than 1.1 M deaths and 40 M cases worldwide with no confirmed remedy yet available. Since the first outbreak in Wuhan, China in December 2019, researchers across the globe have been in a race to develop therapies and vaccines against the disease. SARS-CoV-2, similar to other previously identified Coronaviridae family members, encodes several structural proteins, such as spike, envelope, membrane, and nucleocapsid, that are responsible for host penetration, binding, recycling, and pathogenesis. Structural biology has been a key player in understanding the viral infection mechanism and in developing intervention strategies against the new coronavirus. The spike glycoprotein has drawn considerable attention as a means to block viral entry owing to its interactions with the human angiotensin-converting enzyme 2 (ACE2), which acts as a receptor. Here, we review the current knowledge of SARS-CoV-2 and its interactions with ACE2 and antibodies. Structural information of SARS-CoV-2 spike glycoprotein and its complexes with ACE2 and antibodies can provide key input for the development of therapies and vaccines against the new coronavirus. View Full-Text
Keywords: SARS; COVID-19; structure; spike; receptor binding; antibodies; glycoprotein SARS; COVID-19; structure; spike; receptor binding; antibodies; glycoprotein
Show Figures

Graphical abstract

MDPI and ACS Style

Papageorgiou, A.C.; Mohsin, I. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Cells 2020, 9, 2343. https://doi.org/10.3390/cells9112343

AMA Style

Papageorgiou AC, Mohsin I. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies. Cells. 2020; 9(11):2343. https://doi.org/10.3390/cells9112343

Chicago/Turabian Style

Papageorgiou, Anastassios C., and Imran Mohsin. 2020. "The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies" Cells 9, no. 11: 2343. https://doi.org/10.3390/cells9112343

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop